Jeffrey R Jay
CIK 1239607 · last filed 2017-06-21
Jeffrey R Jay is a corporate insider who has filed 6 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing shows the insider sold $19.5M of ADMS on Jun 21, 2017. Across all open-market trades the lifetime net is −$27.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $57.3M across reported positions. 56 SEC filings were submitted jointly with GREAT POINT PARTNERS LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ADMS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
165 MASON STREET, 3RD FLOOR
GREENWICH, CT 06830
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Adamas Pharmaceuticals Inc (ADMS) Delisted | 10%+ Owner | 2,231,351 | $8.22 | $18.34M | -$19.47M | 1 | 2017-06-21 |
| MEMY | 10%+ Owner | 4,079,270 | $14.05 | $57.31M | -$3.36M | 3 | 2008-12-11 |
| MEDecision, Inc. (MEDE) Delisted | 10%+ Owner | 996,574 | — | — | -$4.25M | 1 | 2008-07-09 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-21 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Sell (S) | −1,140,000 | -$19.47M | EDGAR |
| 2009-01-08 | — | U | −26,477,280 | -$16.15M | |
| 2008-12-11 | MEMY | Sell (S) | −2,931,675 | -$1.73M | EDGAR |
| 2008-07-09 | MEDecision, Inc. (MEDE) Delisted | Mixed | −646,296 | -$4.25M | EDGAR |
| 2007-10-22 | MEMY | Sell (S) | −1,718,000 | -$1.63M | EDGAR |
| 2007-01-23 | MEMY | Exer (X) | +4,986,478 | $5.53M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.